Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Salix Pharmaceuticals Ltd., a prominent player in the pharmaceutical industry, is headquartered in the United States and focuses primarily on gastrointestinal disorders. Founded in 2001, the company has made significant strides in developing innovative therapies that address unmet medical needs, particularly in the areas of irritable bowel syndrome and inflammatory bowel disease.
Salix is renowned for its core products, including prescription medications that offer unique mechanisms of action, setting them apart in a competitive market. With a strong commitment to research and development, Salix has achieved notable milestones, solidifying its position as a leader in gastrointestinal health. The company continues to expand its operational reach, serving patients across North America and beyond, while maintaining a focus on delivering high-quality, effective treatments.
-9 vs industry average
Salix Pharmaceuticals Ltd.’s score of 33 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Salix Pharmaceuticals Ltd. yet.
Salix Pharmaceuticals Ltd., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Bausch Health Companies Inc., which may influence its climate commitments and reporting practices.
While there are no documented reduction targets or climate pledges specific to Salix Pharmaceuticals, it is important to note that any potential climate initiatives or targets would likely be aligned with those set by its parent company, Bausch Health Companies Inc. This includes commitments to sustainability and emissions reduction that may cascade down to Salix Pharmaceuticals.
As of now, Salix Pharmaceuticals has not disclosed any specific initiatives or targets related to the Science Based Targets initiative (SBTi) or other industry-standard climate frameworks. The lack of emissions data and reduction commitments highlights an opportunity for the company to enhance its environmental accountability and transparency in the future.
No climate goals have been disclosed for Salix Pharmaceuticals Ltd. yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more